Rajnath Singh Praises Modi’s ‘Aatmanirbhar Bharat’ Vision As Vaccines Get Green Sign
After the Controller General of Drugs of India (DCGI) gave the green signal to two candidate vaccines for restricted and emergency use on Sunday, Union Minister Rajnath Singh praised Prime Minister Narendra Modi’s vision for Aatmanirbhar Bharat, who said that he has greatly helped India to come. with indigenous solutions in India’s fight against the global pandemic.
“India today takes a giant step towards the decisive defeat of the Covid-19 pandemic with DCGI granting approval to vaccines from the Serum Institute of Bharat Biotech. We are proud of our scientists who made this vaccine possible in a very short time, ”Rajnath tweeted.
Several ministers took to Twitter on Sunday to congratulate the collaborative effort of scientists, vaccine makers. “A great and historic moment for India. Indian vaccines are a reality now. Thank you Narendra Modiji for this significant and heartwarming announcement, ”said Minister Prakash Javadekar.
Calling it a “moment of pride”, Minister Nitin Gadkari congratulated Prime Minister Modi under “whose leadership our scientists have accomplished this in such a short time.”
The Indian government’s chief scientific adviser, K Vijay Raghavan, said that vaccination will start soon. “This is the result of the focused work of scientists, national laboratories, government agencies, regulators, healthcare workers, and most importantly, all of our people who have waited patiently following all the appropriate Covid-19 behavior,” he tweeted .
Both Covishield and Covaxin are indigenous. Although Covishield has been developed by the University of Oxford in collaboration with Astrazeneca, the Serum Institute of India in Pune is its manufacturing partner in India. SII also conducted the second phase trial in India and the third phase trial is ongoing. On the other hand, Covaxin from Bharat Biotech is completely indigenous, as it has been developed in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology (NIV).
Both vaccines have great prospects in the international market, as several countries have shown interest in these two vaccines.